Patent ID: 8277807
Filing Date: 2012-10-02
Classification: A61K,A61P

Abstract:
1. A combination comprising one or more ancillary compound(s) and a compound of the formula (VI): or a salt, solvate, tautomer or N-oxide thereof; wherein the bicyclic group: is selected from the structures Cl, C5 and C6: wherein n is 0, 1, 2 or 3; R R R R R R halogen; hydroxy; trifluoromethyl; cyano; nitro; carboxy; amino; mono- or di-C carbocyclic and heterocyclic groups having from 3 to 12 ring members; and a group R wherein the one or more ancillary compound(s) is selected from the group consisting of: I. corticosteroids, antiandrogens, antiestrogens, aromatase inhibitors and GNRAs; II. interferons and interleukins; III. tretinoin, alitretinoin and bexarotene; IV. rituximab, tositumomab and gemtuzumab ozogamicin; alemtuzumab, alemtuzumab, and bevacizumab; V. camptothecin compounds; VI. 5-fluorouracil, capecitabine, gemcitabine, cytarabine, fludarabine, raltitrexed, pemetrexed and methotrexate; VII. vinca alkaloids; VIII. taxanes; IX. epothilones; X. platinum compounds; XI. anthracycline derivatives, mitoxantrone and podophyllotoxin derivatives; XII. aziridines, nitrogen mustards, nitrosurea alkylating agents and bisalkanesulfonates; XIII. CDK inhibitors; XIV. COX-2 inhibitors; XV. trichostatin A, suberoylanilide hydroxamic acid, JNJ-16241199, LAQ-824, MGCD-0103, PXD-101; XVI. selective immunoresponse modulators; XVII. temozolomide, decitabine, 5-azacitidine, pseudoisocytidine and 5-fluoro-2′-deoxycytidine; XVIII. bortezimib and bleomycin; XIX. aurora inhibitors; XX. herbimycin, geldanamycin, 17-AAG, 17-DMAG, CNF-2024, and IPI-504; XXI. checkpoint targeting agents; XXII. DNA repair inhibitors; XXIII. inhibitors of G-protein coupled receptor inhibitors; XXIV. trastuzumab, cetuximab, panitumumab, tipifamib, gefitinib, erlotinib, bevacizumab, sunitinib, imatinib mesylate, sorafenib dasatinib, lapatinib, nilotinib, vandetanib, vatalinib and CHIR-258 and XXV. anti-emetic agents, agents that prevent or decrease the duration of chemotherapy associated neutropenia and prevent complications that arise from reduced levels of red blood cells or white blood cells, agents that inhibit bone resorption, bisphosphonate agents, agents that suppress inflammatory responses, agents that reduce blood levels of growth hormone and IGF-I in acromegaly patients, antidotes to drugs that decrease levels of folic acid, and agents for the treatment of oedema and thromoembolic episodes.